Results 91 to 100 of about 21,980 (135)

Moving beyond cytotoxicity in cancer immunotherapy: embracing tumor microenvironment remodeling for durable control. [PDF]

Br J Cancer
Koelsch N, Manjili MH.
europepmc   +1 more source

Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy. [PDF]

Immunotargets Ther
Liu Q, Li L, Nian S, Sun X, Guo X, Li C, Yang Z, Ye Y, Yuan Q.   +8 more
europepmc   +1 more source

Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice [PDF]

, 2006
Fukushima, A., Yamaguchi, T., Azuma, M., Yagita, H., Ueno, H.   +4 more
core   +1 more source

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. [PDF]

NPJ Precis Oncol
Marchesi S, Marinello A, Ambrosini P, Cavalli C, Lo Russo G, Occhipinti M.   +5 more
europepmc   +1 more source

Combining immunotherapy with radiation therapy in thoracic oncology [PDF]

, 2018
Badiyan, Shahed N, Chilukuri, Srinivas, Chuong, Michael D, Glass, Erica, Mohindra, Pranshu, Onyeuku, Nasarachi E, Remick, Jill, Rice, Stephanie R, Roach, Michael C, Simone, Charles B, II   +9 more
core   +1 more source

Discrepant CD3+ TILs in PD-L1-Negative NSCLC: Favorable Outcome in an Elderly Patient Treated With Nivolumab, Ipilimumab, and Chemotherapy. [PDF]

Am J Case Rep
Sekiya M, Nakatsugawa M, Koyama N, Kajiwara N, Aoki T.   +4 more
europepmc   +1 more source

Crosstalk between tumor-associated macrophages and the B7/CD28 family in immune checkpoint inhibitor-induced immunotherapy. [PDF]

Mol Cell Biochem
Bai R, Sun W.
europepmc   +1 more source

Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab. [PDF]

J Transl Med
Vanni I, Croce M, Pastorino L, Allavena E, Barbero F, Coco S, Santamaria S, Bosio AG, Boutros A, Rosa A, Fontana V, Spagnolo F, Ghiorzo P, Tanda ET.   +13 more
europepmc   +1 more source

Intrapatient variation in PD-L1 expression and tumor mutational burden and implications for outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. [PDF]

J Immunother Cancer
Li G, Xu J, Tian X, Xiao J, Long J, Chen Y, Shen W, Zhao S.   +7 more
europepmc   +1 more source

The Attractiveness of B7-H3 as a Target for Lung Cancer Treatment. [PDF]

Cancers (Basel)
Papavassiliou KA, Sofianidi AA, Papavassiliou AG.   +2 more
europepmc   +1 more source